SAN DIEGO, CA / ACCESS Newswire / October 14, 2026 / Ablexis, LLC, a biopharmaceutical company focused on advancing human antibody drug discovery through provision of its AlivaMab® Mouse technology, announced today an agreement granting Novo Nordisk A/S (Novo) a non-exclusive license to Ablexis' proprietary AlivaMab Mouse human antibody drug discovery platforms to discover, develop, and commercialize biologics drugs comprising AlivaMab antibodies. The license provides Novo rights to possess and use AlivaMab Mouse strains for the generation of human VH/VL antibodies.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.